InvestorLens

BMY — BRISTOL-MYERS SQUIBB CO

Health Care · Drug Manufacturers

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying BMY?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
80
Institutional Conviction
Strong distribution · 1 buying vs 4 selling last quarter
19
Macro Tailwind
Macro conditions are mixed for this sector
53
Congressional Activity
1 congressional purchase, 0 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 5 tracked investors who changed their BMY position last quarter, 1 bought and 4 sold (20% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 53/100 in a Overheat regime). 1 congressional purchase, 0 sales disclosed in the last 6 months.

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Steve Cohen)
  • +4 tracked investors reported holding BMY at their latest filing
Contradicting evidence — always shown
  • −4 tracked investors reduced or exited last quarter (3 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About BRISTOL-MYERS SQUIBB CO (BMY)

BRISTOL-MYERS SQUIBB CO (BMY) appears in the most recent 13F filings of 4 tracked institutional investors. BRISTOL-MYERS SQUIBB CO is classified in the Health Care sector (Drug Manufacturers industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $1.1B. Across recent filings, tracked investors recorded 5 new positions, 15 increased, 20 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in BMY

48
/100
Mixed Activity
Added / Increased20
Reduced20
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track BMY

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

BMY Ownership Composition

How BRISTOL-MYERS SQUIBB CO is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
99% of tracked value
Institutions
4
tracked investors
Total Reported
$614.4M
combined 13F value
Types2
  • Multi-Strategy / Quant98.9%
  • Macro1.1%
Multi-Strategy / Quant(3)
98.9%
Macro(1)
1.1%

Tracked investors currently reporting BMY

1 tracked investor has since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    7.7M
    Value
    $442.9M
    % Portfolio
    0.05%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    1.5M
    Value
    $86.4M
    % Portfolio
    0.03%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    1.4M
    Value
    $78.3M
    % Portfolio
    0.09%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    117.9K
    Value
    $6.8M
    % Portfolio
    0.01%

Previously held BMY

These investors reported BMY in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Ray DalioBridgewater Associates241.7K$14.7MMar 31, 2026

Recent activity

Frequently asked questions

How many institutional investors hold BMY?
4 tracked institutional investors disclosed a position in BMY (BRISTOL-MYERS SQUIBB CO) in their most recent 13F filing.
Who is the largest institutional holder of BMY?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in BMY, valued at $1.1B.
Did institutional ownership of BMY increase or decrease?
Across recent 13F filings, tracked investors recorded 5 new positions, 15 increased, 20 reduced, and 2 fully exited BMY.
What sector is BMY in?
BRISTOL-MYERS SQUIBB CO is classified in the Health Care GICS sector, Drug Manufacturers industry.
Where does this BMY ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.